Skip to contentSkip to filters

We use cookies for analytics.

Grant

Clinical Research Studies of Atirmociclib in HR+/HER2- and/or HER2+ Breast Cancer

Pfizer

  • Brazil, Mexico, Canada, Australia, France, Germany, Italy, Spain, United Kingdom, China, Japan, South Korea, Taiwan, United States
  • Institution applies
  • Oncology, Clinical Pharmacology and
Related content

About

Supports clinical studies of atirmociclib in breast cancer. Investigators can address recurrence after adjuvant CDK4/6 inhibition, combinations in hormone receptor-positive metastatic disease, or early clinical signals in HER2-positive disease.

Topics

Eligibility

Covers: Pfizer has allocated USD 8 million across up to six clinical studies lasting three years.

The geographic scope of the call is BR, MX, CA, AU, FR, DE, IT, ES, GB, CN, JP, KR, TW, US.

cdn.pfizer.compfizer.com

The institution and principal investigator must be based in one of the fourteen eligible countries. The principal investigator must be an employee or contractor of the requesting institution.

Source: cdn.pfizer.com